|Year : | Volume
| Issue : | Page :
Can cancer survivors donate convalescent plasma for the treatment of COVID-19?
National Oncology Centre, The Royal Hospital, Muscat, Sultanate of Oman
|Date of Submission||04-Aug-2020|
|Date of Decision||28-Aug-2020|
|Date of Acceptance||15-Sep-2020|
|Date of Web Publication||12-Nov-2020|
National Oncology Centre, The Royal Hospital, Post Box 1331, Seeb, Postal Code 111, Muscat
Sultanate of Oman
Source of Support: None, Conflict of Interest: None
Convalescent plasma (CP) obtained from patients who have recovered from coronavirus disease 2019 (COVID-19) infection contains neutralizing antibodies against the severe acute respiratory syndrome-coronavirus-2 virus and is being used in critically ill patients to boost their immunity. Cancer survivors who are affected by COVID-19 are potential donors of CP. However, twin questions often asked are, firstly, what is the risk of transmitting cancer through blood and blood products donated by a cancer survivor, and secondly, will the CP donated by a cancer survivor have enough antibody titers to have a clinically significant effect? The evidence regarding the safety and efficacy of CP donated by a cancer survivor is examined in this article, and the conclusions are positive. However, regulatory changes will be needed specific to Indian guidelines.
Keywords: Blood donation, cancer survivor, convalescent plasma, COVID-19, neutralizing antibody
| Case Vignette|| |
SS is a 50-year-old female treated for Stage III colon cancer in 2010 and on 6-monthly follow-up. She missed her scheduled review in July 2020 and informed that she could not come on for her appointment due to COVID-19 infection, which affected her whole family, all of whom had mild symptoms and recovered uneventfully. I suggested that she could now donate convalescent plasma (CP) for the treatment of seriously ill COVID-19 patients, and she was immediately interested. I advised her to go to the hospital's blood transfusion center and volunteer. Later, I had a call from the Transfusion Medical Officer asking me to clarify whether cancer survivors can donate blood or blood products.
| Introduction|| |
Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), is the latest virus in the long line of infectious agents that have challenged human beings through our history. The pandemic started with an outbreak of pneumonia of unknown origin in Wuhan in the Hubei province of China in December 2019. By January 7, 2020, Chinese scientists had isolated the causative novel coronavirus (CoV). The Chinese flu spread rapidly through China and was exported, initially to Thailand, Japan, Korea, the USA, Vietnam, and Singapore, and later to the rest of the world. As of August 03, 2020, there are over 18 million recorded cases with about 700,000 deaths in 213 countries (www.worldometer.info).
The methods of managing the COVID-19 patients have varied widely across the world and continue to evolve. There is a tacit understanding that the final control over the virus will be achieved only when there is herd immunity, either by active infection or by a vaccine (the exact percentage of immune population required for this remains a matter of controversy). In the meantime, prevention by measures such as social distancing, hand washing, and face masks has been recommended to “flatten the curve,” thus spreading out the cases, and avoid overwhelming the health-care facilities by unmanageable spikes in symptomatic cases needing active treatment. The role of pharmacological agents in prevention, such as hydroxychloroquine, is controversial.
Treatment of symptomatic cases depends on the severity and in addition to the management of complications, is a two-pronged approach – anti-viral agents (only remdesivir has a high level of evidence) and anti-inflammatory drugs (again, only dexamethasone has a high level of evidence). An indirect way of targeting the virus is by boosting host immunity with the use of CP.
Passive antibody therapy through transfusion of CP is a short-term strategy for conferring immediate immunity and has been used in the past for similar viral epidemics such as Middle East respiratory syndrome and SARS-1. Readers are referred to an excellent review by Bloch et al. for details of this therapy. CP (or immune) is a plasma containing neutralizing antibodies (NAbs) to a specific infection collected from previously infected individuals after resolution of infection. Many of the initial studies displaying the positive effects of CP have been from China. A systematic review of five studies (four from China) confirmed the beneficial effects in almost all patients, including a rise in NAb titers and disappearance of circulating CoV-2 RNA, and possible reduction in mortality. However, a large Cochrane analysis of CP reported that the safety and efficacy of CP in COVID-19 patients were “uncertain,” and that data from the ongoing 98 studies (including 50 randomized trials) are awaited.
The CP donor must have had a molecularly confirmed COVID-19 infection (such as RT-PCR positivity of nasopharyngeal swab), recovery from symptoms of at least 14 days, and a negative test subsequently (to prevent transmission to blood transfusion department staff). However, the last criterion is not absolute as it is accepted that most cases of mild infection will clear the virus by the 10th day.
A Chinese study of 175 patients who recovered from mild COVID-19 infection showed that most COVID-19 patients developed SARS-CoV-2-specific NAbs by the convalescent phase of infection. However, 30% had low titers and 10 of them had undetectable levels – it was not clear how they recovered without generating an antibody response. The titers of NAbs reached their peak at 10–15 days after the disease onset and that antibodies targeting on different domains of S protein, including S1, RBD, and S2, contributed to virus neutralization. These and other studies indicate that seroconversion of the donor occurs between day 8 and 21 after the onset of symptoms, and peak antibody titers are obtained 14 days after the resolution of symptoms. The relation between total and NAbs is not clear.
Theoretically, the CP should be tested for antibody titers before transfusion, but tests for specific NAbs are not generally available and quantitative assays for total antibodies (such as ELISA) have not yet been validated. The Indian government guidelines suggest that in the case of nonavailability of tests for NAbs, plasma IgG titer (against S-protein RBD) above 1:640 should be used.
The collection and administration of CP follows standard procedure, but it is recommended that apheresis be used rather than whole blood donation; this will yield 400–800 mL of plasma, enough for two to four units of CP. The units are frozen after collection while awaiting standard donor testing such as for other infections. A typical patient, usually critically ill, need only one or two units of CP for treatment. This should provide adequate titers which last from few weeks to few months.
The transient nature of antibody response is a matter of concern. A recent letter to the New England Journal of Medicine suggests that there is a rapid fall in antibody titers (half life of 36 days) after recovery from mild infection – this may not be important for the survivor as re-exposure could result in rapid recovery due to memory B cells, but suggests that CP may not contain adequate antibody titers if collection is delayed. Another paper from Kings College, London, reported that the antibodies appear in >95% of cases after 8 days of symptoms, but levels began to fall about a month later, sometimes to nearly undetectable levels. Hence, the window of opportunity for donation and the donor pool could be smaller than estimated.
| Cancer and Covid-19|| |
The risk factors associated with the severity of infection and mortality of COVID-19 infection include male sex, age, obesity, comorbid medical conditions (diabetes, chronic obstructive pulmonary disease, and chronic kidney failure), and cancer. The initial and subsequent papers, from China indicated an increased severity and mortality in cancer patients, leading to extraordinary changes in their management. However, more recent papers, suggest that the risk is exaggerated and may be limited to specific subsets, such as those with hematological malignancies and those on immunotherapy. Indeed, there is a possibility that prostate cancer patients on androgen deprivation therapy may actually be protected, consistent with epidemiological data that women are less affected (it would be interesting to see whether patients at the other end of the spectrum, i.e., post-menopausal women with breast cancer on aromatase inhibitor therapy are more at risk).
| Blood Donation by Cancer Patients|| |
Blood donation by cancer survivors is a matter of controversy due to a theoretical risk of transmitting cancer by circulating tumor cells. Donor-transmitted cancer has been reported in recipients of organ transplantation; however, cancer transmission through donation of blood or blood products is unknown. Large vein-to-vein databases are maintained to monitor the health of donors and specific recipients for infectious and noninfectious early and late complications, which have not reported any such transmission. For instance, the Scandinavian Donations and Transfusions database examined 354,094 transfused patients, of whom 3% received at least one blood unit from a precancerous donor (defined as someone who developed a cancer within 5 years of donating blood). There was no difference in the cancer incidence or site of cancer in them, compared to those who received blood donation from those who remained cancer free in those 5 years.
In spite of such consistent data, the guidelines allowing cancer patients to donate blood vary by country and organization. The Joint United Kingdom Blood Transfusion and Tissue Transplantation Services permits only those with treated basal cell carcinoma or in situ cancer or premalignant conditions (such as polyposis coli) to donate blood. On the other hand, most hospitals in the USA permit blood donation if the survivor has been off treatment for >12 months without recurrence. However, hematological malignancies (leukemias, lymphomas, and myeloma) bring with it a lifelong bar on donation. This is in line with the recommendations of the American Red Cross. Hence, there is no reason why cancer and COVID-19 survivors (double survivors) should not donate CP. However, the Indian guidelines in their donor selection criteria state that malignancy is a reason for permanent deferment – there is an urgent need to reexamine this.
| Antibody Titers in Cancer Survivors|| |
As of January 2019, it is estimated that there are 16.9 million cancer survivors in the USA, representing approximately 5.0% of the population. This is a heterogeneous population and at higher risk for second primary malignancy, both due to inherited genetic defects and effects of cancer drugs, and with long-term immune abnormalities. Immunization schedule for cancer patients and survivors is different from that of general population and include contraindication to live vaccines., It is assumed that cancer and its treatment could lead to lowered immunity, which raises the question whether COVID-19/cancer survivors can generate sufficient antibody titers. At present there is no direct data on this, but as recent papers indicate equivalent survival in cancer patients affected by coronavirus, it can be assumed that they too generate an adequate antibody response.
Poor antibody responses to vaccines are common in patients of hematological malignancies, especially those who receive anti-B cell agents such as rituximab. Among patients with Hodgkin lymphoma, for example, vaccine responses remain impaired for as long as 7 years after treatment. However, such survivors of hematological malignancies are automatically excluded from CP donation. On the other hand, patients with solid tumors are classically given myelosuppressive rather than immunosuppressive therapy. Hence, the degree of immunosuppression is expected to be minimal. Consistent with this, no deficiency in serologic response was noted in patients with solid tumors, such as gastric and colorectal cancers, vaccinated with pneumococcal vaccine, or influenza vaccine. They have responded with adequate antibody titers. Thus, both direct and indirect evidence suggests that survivors of solid tumors who recovered from COVID-19 will have equivalent NAbs. However, this requires confirmation.
| Conclusions|| |
Cancer survivors who survive COVID-19 (double survivors) are expected to have sufficient NAb titers in their plasma to be considered for CP donation. The risk of transmitting cancer through blood or blood products is negligible to nonexistent. Recent data indicate that patients recovering from mild coronavirus infection (representing about 85% of the infected population) have a limited period for donating their plasma due to rapid decay of antibody titers; this suggests that the donor pool is smaller than estimated. Cancer survivors form a not-so-negligible percentage of the population and they are well aware of the importance of blood transfusion by personal experience. Consequently, they are well motivated to donate. It can be concluded that CP donation by survivors of solid tumors who are free of recurrences for at least 12 months after treatment is safe and of equivalent efficacy. In the meantime, there is an urgent need to revise the guidelines by the Indian regulatory authorities banning donation of blood and blood products by cancer survivors.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Morens DM, Daszak P, Markel H, Taubenberger JK. Pandemic COVID-19 Joins History's Pandemic Legion. mBio 2020;11:e00812-20.
Kulkarni P, Dhanushkodi M. Novel coronavirus severe acute respiratory syndrome-coronavirus 2 (coronavirus disease 2019): We shall overcome! Indian J Med Paediatr Oncol 2020;41:110-3.
MacIntyre CR, Wang Q. Physical distancing, face masks, and eye protection for prevention of COVID-19. Lancet 2020;395:1950-1.
RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al
. Dexamethasone in hospitalized patients with Covid-19-Preliminary report. N
Engl J Med. 2020 Jul 17:NEJMoa2021436. doi: 10.1056/NEJMoa2021436. [Epub ahead of print].
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al
. Remdesivir for the treatment of Covid-19-Preliminary report. N
Engl J Med 2020;383:992-4. [doi: 10.1056/NEJMoa2007764].
Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL, et al
. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest 2020;130:2757-65.
Rajendran K, Krishnasamy N, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVID-19: Systematic review. J Med Virol 2020;92:1475-83. [doi: 10.1002/jmv.25961].
Piechotta V, Chai KL, Valk SJ, Doree C, Monsef I, Wood EM, et al
. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: A living systematic review. Cochrane Database Syst Rev 2020;7:CD013600.
Wu F, Wang A, Liu M, Lu L, Wang Q, Gu C, et al
. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv 2020. pre-print. [doi: 10.1101/2020.03.30.20047365].
Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al
. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med 2020;26:845-8.
Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, et al
. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild COVID-19. N
Engl J Med 2020;383:1085-7.
Seow J, Graham C, Merrick B, Acors S, Steel KJ, Hemmings O, et al
. Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. medRxiv 2020. pre-print. [doi: 10.1101/2020.07.09.20148429].
Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China. JAMA Oncol 2020;6:1108-10.
Dai MY, Liu D, Liu M, Zhou F, Li G, Chen Z, et al
. Patients with cancer appear more vulnerable to SARS-CoV-2: A multi center study during the COVID-19 outbreak. Cancer Discov 2020;10:783-91.
Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al
. Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China. Lancet Oncol 2020;21:335-7.
Pathak R, Chitkara G, Kulkarni P, Bhattacharyya GS, Gupta S, Bajpai J. Tale of constant adaptation, revision, and change of cancer therapy during the ongoing COVID crisis: Adapting to cope and win. Indian J Med Paediatr Oncol 2020;41:103-9. [Full text]
van Dam PA, Huizing M, Mestach G, Dierckxsens S, Tjalma W, Trinh XB, et al
. SARS-CoV-2 and cancer: Are they really partners in crime? Cancer Treat Rev 2020;89:102068.
Lee LY, Cazier JB, Angelis V, Arnold R, Bisht V, Campton NA, et al
. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: A prospective cohort study. Lancet 2020;395:1919-26.
Robilotti EV, Babady NE, Mead PA, Rolling T, Perez-Johnston R, Bernardes M, et al
. Determinants of severity in cancer patients with COVID-19 illness. medRxiv 2020. pre-print [doi: 10.1101/2020.05.04.20086322].
Montopoli M, Zumerle S, Vettor R, Rugge M, Zorzi M, Catapano CV, et al
. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: A population-based study (N=4532). Ann Oncol 2020;31:1040-5.
Desai R, Collett D, Watson CJ, Johnson P, Evans T, Neuberger J. Cancer transmission from organ donors-unavoidable but low risk. Transplantation 2012;94:1200-7.
Yang H, Lee J, Seed CR, Keller AJ. Can blood transfusion transmit cancer? A literature review. Transfus Med Rev 2010;24:235-43.
Goel R, Tobian AAR, Shaz BH. Noninfectious transfusion-associated adverse events and their mitigation strategies. Blood 2019;133:1831-9.
Edgren G, Hjalgrim H, Reilly M, Tran TN, Rostgaard K, Shanwell A, et al
. Risk of cancer after blood transfusion from donors with subclinical cancer: A retrospective cohort study. Lancet 2007;369:1724-30.
Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, et al
. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin 2019;69:363-85.
Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al
. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014;58:e44-100.
Shah MK, Kamboj M. Immunizing cancer patients: Which patients? Which vaccines? When to give? Oncology (Williston Park) 2018;32:254-C3.
Nazi I, Kelton JG, Larché M, Snider DP, Heddle NM, Crowther MA, et al
. The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood 2013;122:1946-53.
Frederiksen B, Specht L, Henrichsen J, Pedersen FK, Pedersen-Bjergaard J. Antibody response to pneumococcal vaccine in patients with early stage Hodgkin's disease. Eur J Haematol 1989;43:45-9.
Choi W, Kim JG, Beom SH, Hwang JE, Shim HJ, Cho SH, et al
. Immunogenicity and optimal timing of 13-valent pneumococcal conjugate vaccination during adjuvant chemotherapy in gastric and colorectal cancer: A randomized controlled trial. Cancer Res Treat 2020;52:246-53.
Nordøy T, Aaberge IS, Husebekk A, Samdal HH, Steinert S, Melby H, et al
. Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae
. Med Oncol 2002;19:71-8.